Heparan sulfate proteoglycans present PCSK9 to the LDL receptor-Reference-Cited by-同舟云学术

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor

Published:2017-09-11 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Gustafsen Camilla^ORCID,Olsen Ditte,Vilstrup Joachim^ORCID,Lund Signe,Reinhardt Anika,Wellner Niels,Larsen Torben,Andersen Christian B. F.,Weyer Kathrin,Li Jin-ping,Seeberger Peter H.,Thirup Søren^ORCID,Madsen Peder,Glerup Simon

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-017-00568-7.pdf

Reference63 articles.

1. Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161, 161–172 (2015).

2. Ahmad, Z. Statin intolerance. Am. J. Cardiol. 113, 1765–1771 (2014).

3. Awan, Z. et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin. Chem. 58, 183–189 (2012).

4. Dubuc, G. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454–1459 (2004).

5. Seidah, N. G., Awan, Z., Chretien, M. & Mbikay, M. PCSK9: a key modulator of cardiovascular health. Circ. Res. 114, 1022–1036 (2014).

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The singular French PCSK9-p.Ser127Arg gain-of-function variant: a significant player in cholesterol levels from a 775-year-old common ancestor;Atherosclerosis;2024-09

2. The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms;Frontiers in Cardiovascular Medicine;2024-08-01

3. Enhancing genotype-phenotype association with optimized machine learning and biological enrichment methods;2024-06-15

4. PCSK9 inhibitors: a patent review 2018-2023;Expert Opinion on Therapeutic Patents;2024-04-02

5. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial;Circulation;2024-01-16